Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-19T23:28:01.612Z Has data issue: false hasContentIssue false

Chapter 37 - Allogeneic Hematopoietic Cell Transplants for BCR/ABL Negative Myeloproliferative Neoplasms

from Section 11 - Hematopoietic Cell Transplants for Myeloproliferative Neoplasms

Published online by Cambridge University Press:  24 May 2017

By
Nicolaus Kröger
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 351 - 360
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Tefferi, A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520–30.CrossRefGoogle ScholarPubMed
Mesa, RA, Verstovsek, S, Cervantes, F, Barosi, G, Reilly, JT, Dupriez, B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737–40.CrossRefGoogle Scholar
Cervantes, F, Dupriez, B, Pereira, A, Passamont, F, Reilly, JT, Morra, E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.CrossRefGoogle Scholar
Passamonti, F, Cervantes, F, Vannucchi, AM, Morra, E, Rumi, E, Pereira, A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–08.CrossRefGoogle Scholar
Caramazza, D, Begna, KH, Gangat, N, Vaidya, R, Siragusa, S, Van Dyke, DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82–8.CrossRefGoogle ScholarPubMed
Tefferi, A, Siragusa, S, Hussein, K, Schwager, SM, Hanson, CA, Pardanani, A, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010;85(1):14–7.CrossRefGoogle ScholarPubMed
Gangat, N, Caramazza, D, Vaidya, R, George, G, Begna, K, Schwager, S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.CrossRefGoogle Scholar
Guglielmelli, P, Lasho, TL, Rotunno, G, Score, J, Mannarelli, C, Pancrazzi, A, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804–10.CrossRefGoogle Scholar
Kerbauy, DM, Gooley, TA, Sale, GE, Flowers, ME, Doney, KC, Georges, GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355–65.CrossRefGoogle ScholarPubMed
Kralovics, R, Passamonti, F, Buser, AS, Teo, SS, Tiedt, R, Passweg, JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90.CrossRefGoogle ScholarPubMed
James, C, Ugo, V, Le Couedic, JP, Staerk, J, Delhommeau, F, Lacout, C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 2005;434(7037):1144–8.CrossRefGoogle ScholarPubMed
Verstovsek, S, Kantarjian, H, Mesa, R, Pardanani, AD, Cortes-Franco, J, Thomas, DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Eng J Med. 2010;363(12):1117–27.CrossRefGoogle ScholarPubMed
Harrison, C, Kiladjian, JJ, Al-Ali, HK, Gisslinger, H, Waltzman, R, Stabovskaya, V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Eng J Med. 2012;366(9):787–98.CrossRefGoogle ScholarPubMed
Verstovsek, S, Mesa, RA, Gotlib, JR, Levy, RS, Gupta, V, DiPersio, JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Eng J Med. 2012;366(9):799–807.CrossRefGoogle ScholarPubMed
Cervantes, F, Vannucchi, AM, Kiladjian, JJ, Al-Ali, HK, Sirulnik, A, Stalbovskaya, V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122(25):4057–3.CrossRefGoogle ScholarPubMed
Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, DiPersio, JF, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865–71.CrossRefGoogle ScholarPubMed
Passamonti, F, Maffioli, M, Cervantes, F, Vannucchi, AM, Morra, E, Barbui, T, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123(12):1833–5.CrossRefGoogle ScholarPubMed
Dokal, I, Jones, L, Deenmamode, M, Lewis, SM, Goldman, JM. Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol. 1989;71(1):158–60.CrossRefGoogle ScholarPubMed
Creemers, GJ, Lowenberg, B, Hagenbeek, A. Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol. 1992;82(4):772–3.CrossRefGoogle ScholarPubMed
Guardiola, P, Anderson, JE, Bandini, G, Cervantes, F, Runde, V, Arcese, W, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Franҁaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93(9):2831–8.Google Scholar
Deeg, HJ, Gooley, TA, Flowers, ME, Sale, GE, Slattery, JT, Anasetti, C, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102(12):3912–18.CrossRefGoogle ScholarPubMed
Daly, A, Song, K, Nevill, T, Nantel, S, Toze, C, Hogge, D, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003;32(1):35–40.CrossRefGoogle ScholarPubMed
Byrne, JL, Beshti, H, Clark, D, Ellis, I, Haynes, AP, Das-Gupta, E, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect. Br J Haematol. 2000;108(2):430–3.CrossRefGoogle ScholarPubMed
Cervantes, F, Rovira, M, Urbano-Ispizua, A, Rozman, M, Carreras, E, Montserrat, E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000;26(6):697–9.CrossRefGoogle ScholarPubMed
Hessling, J, Kröger, N, Werner, M, Zabelina, T, Hansen, A, Kordes, U, et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;119(3):769–72.CrossRefGoogle ScholarPubMed
Devine, SM, Hoffman, R, Verma, A, Shah, R, Bradlow, BA, Stock, W, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99(6):2255–8.CrossRefGoogle ScholarPubMed
Rondelli, D, Barosi, G, Bacigalupo, A, Prchal, U, Alessandrino, EP, Spivak, JL, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105(10):4115–9.CrossRefGoogle ScholarPubMed
Kröger, N, Zabelina, T, Schieder, H, Panse, J, Ayuk, F, Stute, N, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128(5):690–7.CrossRefGoogle ScholarPubMed
Kröger, N, Holler, E, Kobbe, G, Bornhäuser, M, Schwerdtfeger, R, Baurmann, H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264–70.Google ScholarPubMed
Alchalby, H, Zabelina, T, Wollf, D, Kobbe, G, Bornhäuser, M, Baurmann, H, et al. Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2011;118: Abstract 1019.Google Scholar
Rondelli, D, Goldberg, J, Isola, L, Price, LS, Shore, TB, Boyer, M, et al. MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124(7):1183–91.CrossRefGoogle ScholarPubMed
Bacigalupo, A, Soraru, M, Dominietto, A, Pozzi, S, Geroldi, S, Van Lint, MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen, and donor type. Bone Marrow Transplant. 2010;45(3): 458–63.CrossRefGoogle ScholarPubMed
Gupta, V, Malone, AK, Hari, PN, Ahn, KW, Hu, ZH, Gale, RP, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014;20(1): 89–97.CrossRefGoogle ScholarPubMed
Stewart, WA, Pearce, R, Kirkland, KE, Bloor, A, Thomson, K, Apperley, J, et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant. 2010;45(11):1587–93.CrossRefGoogle ScholarPubMed
Ballen, KK, Shrestha, A, Sobocinski, KA, Zhang, MJ, Bashey, A, Bolwell, BJ, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358–67.CrossRefGoogle ScholarPubMed
Robin, M, Tabrizi, R, Mohty, M, Furst, S, Michallet, M, Bay, JO, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Franҁaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331–9.CrossRefGoogle Scholar
Gupta, V, Kröger, N, Aschan, J, Xu, W, Leber, B, Dalley, C, et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant. 2009;44(5):317–20.CrossRefGoogle ScholarPubMed
Abelsson, J, Merup, M, Birgegard, G, Weis Bjerrum, O, Brinch, L, Brune, M, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant. 2012;47(3):380–6.CrossRefGoogle ScholarPubMed
Ditschkowski, M, Elmaagacli, AH, Trenschel, R, Gromke, T, Steckel, NK, Koldehoff, M, et al. Dynamic International Prognostic Scoring scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica. 2012;97(10):1574–81.CrossRefGoogle ScholarPubMed
Scott, BL, Gooley, TA, Sorror, ML, Rezvani, AR, Linenberger, ML, Grim, J, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012;119(11): 2657–64.CrossRefGoogle ScholarPubMed
Nivison-Smith, I, Dodds, AJ, Butler, J, Bradstock, KF, Ma, DD, Simpson, JM, et al. Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. Biol Blood Marrow Transplant. 2012;18(2):302–8.CrossRefGoogle ScholarPubMed
Patriarca, F, Bacigalupo, A, Sperotto, A, Isola, M, Soldano, F, Bruno, B, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514–22.CrossRefGoogle ScholarPubMed
Kröger, N, Alchalby, H, Klyuchnnikov, E, Badbaran, A, Hildebrandt, Y, Ayuk, F, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113(8):1866–8.CrossRefGoogle ScholarPubMed
Vainchenker, W, Delhommeau, F, Constantinescu, SN, Bernard, OA. New mutations of myeloproliferative neoplasms. Blood. 2011;118(7):1723–35.CrossRefGoogle ScholarPubMed
Klampfl, T, Gisslinger, H, Harutyunyan, AS, Nivarthi, H, Rumi, E, Milosevic, JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.CrossRefGoogle ScholarPubMed
Nangalia, J, Massie, CE, Baxter, EJ, Nice, FL, Gundem, G, Wedge, DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405.CrossRefGoogle ScholarPubMed
Klyuchnikov, E, Holler, E, Bornhäuser, M, Kobbe, G, Nagler, A, Shimoni, A, et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. 2012;159(2):172–81.CrossRefGoogle ScholarPubMed
Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.CrossRefGoogle ScholarPubMed
Alchalby, H, Yunus, DR, Zabelina, T, Kobbe, G, Holler, E, Bornhäuser, M, et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol. 2012;157(1):75–85.CrossRefGoogle ScholarPubMed
Alchalby, H, Zabelina, T, Stübig, T, van Biezen, A, Bornhäuser, M, Di Bartolomeo, M, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(2):279–81.CrossRefGoogle Scholar
Cahu, X, Chevallier, P, Clavert, A, Suarez, F, Michallet, M, Vincent, L, et al. Allo-SCT for Philadelphia-negative myeloproliferativer neoplasms in blast phase: a study from the Societe Franҁaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2014;49(6):756–60.CrossRefGoogle Scholar
Lussana, F, Rimbaldi, A, Finazzi, MC, van Biezen, A, Scholten, M, Oldani, E, et al. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99(5):916–21.CrossRefGoogle ScholarPubMed
Alchalby, H, Badbaran, A, Zabelina, T, Kobbe, G, Hahn, J, Wolff, D, et al. Impact of JAK2V617F mutation status, alelle burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood. 2010;116(18):3572–81.CrossRefGoogle Scholar
Panagiota, V, Thol, F, Markus, B, Fehse, B, Alchalby, H, Badbaran, A, et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia. 2014;28(7):1552–5.CrossRefGoogle ScholarPubMed
Alchalby, H, Lioznov, M, Fritzsche-Friedland, U, Badbaran, A, Zabelina, T, Bacher, U, et al. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT. Bone Marrow Transplant. 2012;47(1):143–5.CrossRefGoogle ScholarPubMed
Kerbauy, DM, Gooley, TA, Sale, GE, Flowers, ME, Doney, KC, Georges, GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia very, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355–65.CrossRefGoogle ScholarPubMed
Samuelson, S, Sandmaier, BM, Heslop, HE, Popat, U, Carrum, G, Champlin, RE, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age. Br J Haematol. 2011;153(1):76–82.CrossRefGoogle ScholarPubMed
Robin, M, Giannotti, F, Deconinck, E, Mohty, M, Michallet, M, Sanz, G, et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2014;20(11):1841–6.CrossRefGoogle ScholarPubMed
Ciurea, SO, Sadegi, B, Wilbur, A, Alagiozian-Angelova, V, Gaitonde, S, Dobogai, LC, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol. 2008;141(1):80–3.CrossRefGoogle ScholarPubMed
Mesa, RA, Nagorney, DS, Schwager, S, Allred, J, Tefferi, A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361–70.CrossRefGoogle ScholarPubMed
Stübig, T, Alchalby, H, Ditschkowski, M, Wolf, D, Wulf, G, Zabelina, T, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736–8.CrossRefGoogle ScholarPubMed
Tefferi, A, Constantinescu, SN. Introduction to ‘A special spotlight review series on BCR-ABL-negative myeloproliferative neoplasms’. Leukemia. 2008;22(1):3–13.CrossRefGoogle ScholarPubMed
Tefferi, A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255–66.CrossRefGoogle ScholarPubMed
Chagraoui, H, Komura, E, Tulliez, M, Giraudier, S, Vainchenker, W, Wendling, F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100(10):3495–503.CrossRefGoogle ScholarPubMed
Le Bousse-Kerdilès, MC, Martyré, MC, Samson, M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw. 2008;19(2):69–80.Google ScholarPubMed
Thiele, J, Kvasnicka, HM. Grade of bone marrow fibrosis is associated with relevant hematological findings– a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85(4):226–32.CrossRefGoogle Scholar
Barosi, G, Rosti, V, Bonetti, E, Campanelli, R, Carolei, A, Catarsi, P, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLOS One. 2012;7:e35631CrossRefGoogle ScholarPubMed
Gianelli, U, Vener, C, Bossi, A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25(9):1193–202.CrossRefGoogle ScholarPubMed
Nazha, A, Estrov, Z, Cortes, J, Bueso-Ramos, CE, Kantarjian, H, Verstovsek, S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis. Leuk Lymphoma. 2013;54(11):2537–9.CrossRefGoogle ScholarPubMed
Strasser-Weippl, K, Steurer, M, Kees, M, Agustin, F, Tzankov, A, Dirnhofer, S, et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma. 2006;47(3):441–50.CrossRefGoogle ScholarPubMed
Anger, B, Seidler, R, Haug, U, Popp, C, Heimpel, H. Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica. 1990;75(3): 226–34.Google ScholarPubMed
Thiele, J, Kvasnicka, HM, Dietrich, H, Stein, G, Hann, M, Kaminski, A, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol. 2005;20(3):879–89.Google ScholarPubMed
Silver, RT, Vadris, K, Goldman, JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24):6669–72.CrossRefGoogle ScholarPubMed
Tefferi, A, Verstovsek, S, Barosi, G, Passamonti, F, Roboz, GJ, Gisslinger, H, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563–9.CrossRefGoogle ScholarPubMed
Kvasnicka, HM, Thiele, J, Bueso-Ramos, CE, Hou, K, Cortes, JE, Kantarjian, HM, et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. (ASCO Annual Meeting Abstract). J Clin Oncol. 2013;31(15):7030.CrossRefGoogle Scholar
Kröger, N, Zabelina, T, Alchalby, H, Stübig, T, Wolschke, C, Ayuk, F, et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2014;20(6):812–5.CrossRefGoogle ScholarPubMed
Verstovsek, S, Mesa, RA, Gotlib, JR, Levy, RS, Gupta, V, DiPersio, JF, et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF) (ASCO Annual Meeting Abstract). J Clin Oncol. 2011;29(15):6500.CrossRefGoogle Scholar
Harrison, CN, Kiladijan, H, Al-Ali, HK, Gisslinger, H, Waltzman, RJ, Stalbovskaya, V, et al. Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). (ASCO Annual Meeting Abstract). J Clin Oncol. 2011;29(15): LBA6501.Google Scholar
Spoerl, S, Mathew, NR, Bscheider, M, Schmitt-Graeff, A, Chen, S, Mueller, T, et al. Activity of therapeutic JAK ½ blockade in graft-versus-host disease. Blood. 2014;123(24):3832–42.CrossRefGoogle ScholarPubMed
Jaekel, N, Behre, G, Behning, A, Wickenhauser, C, Lange, T, Niederwieser, D, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2):179–84.CrossRefGoogle ScholarPubMed
Robin, M, Francois, S, Huynh, A, Cassimat, B, Bay, JO, Cornillon, J, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the Sfgmtc. Blood. 2013;122(21):abstract 306.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×